Short description
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
Description
RNAimmune is a biopharmaceutical company specializing in the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. The company leverages mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. RNAimmune is a spin-off venture from Sirnaomics, Inc. has received a global exclusive right to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery from Sirnaomics. The company has also developed a proprietary A.I. algorithm (ALEPVA) for antigen prediction and vaccine design. By integrating multiple established platform technologies, the company is aiming to develop a comprehensive mRNA drug discovery and development platform, from which the company will enrich its therapeutic and vaccine product pipeline addressing tremendous unmet needs in treatments of viral infections, cancer, and rare diseases.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Gaithersburg, Maryland, United States, North America
Founded on
January 1, 2020
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
No Way, Cannot Access, Absolutely Noaccess, Absolutely Noaccess
Sign in for full access
Founders
Dong Shen